Systemic vs. Topical Therapy for Vulvovaginal Candidiasis
Author Information
Author(s): Sebastian Faro
Primary Institution: University of Kansas School of Medicine
Hypothesis
The use of short-duration narrow-spectrum agents may increase selection of more resistant organisms, leading to recurrent vulvovaginal candidiasis.
Conclusion
Topical therapy is preferred for treating vulvovaginal candidiasis, especially in pregnant women and those at risk of drug interactions.
Supporting Evidence
- 75% of women will experience at least one episode of vulvovaginal candidiasis in their lifetime.
- 40-50% of women with VVC are likely to have at least one recurrence.
- Topical therapy is recommended for pregnant women and those with potential drug interactions.
Takeaway
This study looks at how to treat a common vaginal infection called candidiasis, suggesting that using creams is often better than pills, especially for pregnant women.
Methodology
The review discusses the efficacy of topical versus systemic treatments for vulvovaginal candidiasis, considering factors like safety, drug interactions, and patient compliance.
Limitations
The study does not provide specific data on the effectiveness of each treatment option or the demographics of the patients involved.
Participant Demographics
The study primarily addresses women of childbearing age, including those who are pregnant or breastfeeding.
Want to read the original?
Access the complete publication on the publisher's website